5-HT 1B receptor Inhibitors
2 drugsAbout 5-HT 1B receptor
The 5-HT1B receptor, or serotonin 1B receptor, is found primarily in the central nervous system and regulates serotonin neurotransmission.
The 5-HT1B receptor is a therapeutic target for CNS disorders, though there is currently no genetic evidence directly linking it to specific diseases.
Two FDA-approved small molecule drugs, SYMBRAVO and MAXALT, target the 5-HT1B receptor for CNS indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
- phase2 represents biological uncertainty with 0% completion.
Top 5-HT 1B receptor Drugs
The competitive landscape includes two companies, AXSOME and Merck, with approved drugs.
Low market concentration suggests relatively low barriers to entry for new competitors.
5-HT 1B receptor Drug Modality Landscape
Modalities
Routes of Administration
5-HT 1B receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities indicates a whitespace opportunity for novel biologics.
5-HT 1B receptor Clinical Trials 46 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 | 100% |
| Phase 2 | 9 | 5 | 2 | 2 | 71% |
| Phase 3 | 21 | 18 | 3 | 0 | 86% |
| Phase 4 | 11 | 4 | 3 | 4 | 57% |
Top Sponsors
By Modality
5-HT 1B receptor Drug Approval Timeline (1998 - 2025)
The first drug was approved in 1998 (MAXALT) and the most recent in 2025 (SYMBRAVO), spanning 28 years.
The long approval span indicates sustained interest, but recent approval suggests renewed opportunity.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 35 clinical trials targeting 5-HT 1B receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities